Shots:
- Voyager to receive $30M up front, $20M as exercise fees for 2 options (exercisable within 12mos.) & ~$580M as development, regulatory & commercial milestones related to licensed products including 2 undisclosed Pfizer’s transgenes along with royalties based on sales of products including licensed capsids
- Pfizer gets the right to assess novel capsids for CNS & cardiac tropisms by utilizing Voyager’s TRACER platform & exercise its options to license capsids for exclusive use in its AAV gene therapies including 2 transgenes
- Voyager holds global rights for all licensed capsids to use with other transgenes & applications of its TRACER technology
Click here to read full press release/ article | Ref: Voyager Therapeutics | Image: Twitter
The post Pfizer Signs an Option and License Agreement with Voyager to Develop and Commercialize Gene Therapies for Neurologic and Cardiovascular Diseases first appeared on PharmaShots.